Hongyu Wu1, Kangmin Zhu, MD, PhD1, John Potter, MD1, Lynn Levin, PhD MPH2, Edward Gorham, PhD MPH3, and Mona Shah, MPH1. (1) US. Military Cancer Institute, 6900 Georgia Ave. NW, Washington, DC 20307-5001, 202-782-3521, firstname.lastname@example.org, (2) Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, (3) Naval Health Research Center, P.O. Box 85122, San Diego, CA 92186
Objective: Some studies have suggested that hepatitis C and possibly hepatitis B increase the risk of B-cell non-Hodgkin’s lymphoma (NHL). Using data from the Selected Cancers Study, we investigated whether self-reported history of hepatitis was associated with NHL and whether the association differed between Caucasian and African American (AA) men. Method: A population-based case-control study was conducted. Cases were 1399 Caucasian and AA men aged 32-60 diagnosed with NHL between 1984 and 1988 and who lived in the regions of eight cancer registries. Controls were 1706 Caucasian and AA men who were frequency-matched to cases by age and cancer registry and selected through random-digit dialing. Men with a history of AIDS or HIV-related behaviors were excluded. Logistic regression analysis was conducted to analyze NHL in relation to hepatitis reported 3 or more years prior to the diagnosis of NHL. Result: The adjusted OR for NHL associated with hepatitis was 0.92 (95% confidence interval (CI): 0.62-1.37). Compared with Caucasian controls, Caucasian cases were not more likely to have a history of hepatitis (OR=0.91, 95% CI: 0.61-1.36). Among AA men, the corresponding OR was 1.28 (95% CI: 0.18-9.13). The results remain similar when B-cell NHL was analyzed as the outcome. Conclusion: History of hepatitis was not associated with the risk of NHL overall or for B-cell NHL for the two race groups, however, analysis based on more specific subtypes of NHL may be warranted.
Keywords: Epidemiology, Cancer
Presenting author's disclosure statement:
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.
The 132nd Annual Meeting (November 6-10, 2004) of APHA